Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OriolaCHIX:ORIOLH 38 Days Sales Outstanding is 603.43 as of Jun. 2026, which is 1138% above its 10-year median of 48.76. GuruFocus rates CHIX:ORIOLH with a GF Score™ of 38/100 and a GF Value™ of €0.72. The stock has 5 warning signs investors should review. Among 656 Healthcare Providers & Services companies, Oriola ranks worse than 85.82% on this metric.
Oriola's average Accounts Receivable for the
three
months ended in Jun. 2026 was €343 Mil. Oriola's Revenue for the
three
months ended in Jun. 2026 was €52 Mil.
Hence, Oriola's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 603.43.
The historical rank and industry rank for Oriola's Days Sales Outstanding or its related term are showing as below:
CHIX:ORIOLh'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.11 Med: 48.76 Max: 110.94
Current: 110.94
During the past 13 years, Oriola's highest Days Sales Outstanding was 110.94. The lowest was 38.11. And the median was 48.76.
CHIX:ORIOLh's Days Sales Outstanding is ranked worse than 85.82% of 656
companies
in the Healthcare Providers & Services industry
Industry Median: 47.355
vs CHIX:ORIOLh: 110.94
Oriola's Days Sales Outstanding
increased
from Jun. 2025 (552.25) to Jun. 2026 (603.43).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Oriola (CHIX:ORIOLh) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Oriola Days Sales Outstanding Related Terms
Oriola Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Oriola's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oriola Days Sales Outstanding Competitor Comparison
For the Pharmaceutical Retailers subindustry, Oriola's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oriola Days Sales Outstanding vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Oriola's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Oriola's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 603.43 mean?
Oriola (CHIX:ORIOLH) has a Days Sales Outstanding of 603.43 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Oriola and its competitors. This is 1138% above median its historical median of 48.76. Over the past decade, Oriola's Days Sales Outstanding has ranged from 38.11 to 110.94. According to the industry distribution chart, Oriola ranks #563 out of 656 companies in the Healthcare Providers & Services industry, placing it in the top 85.8%.
Is Oriola's Days Sales Outstanding too high?
Oriola's current Days Sales Outstanding of 603.43 is 1138% above median its 10-year median of 48.76. Over the past 10 years, this metric has ranged from a low of 38.11 to a high of 110.94. The Healthcare Providers & Services industry median Days Sales Outstanding is 47.36. Oriola's value of 603.43 is 1174.3% above this industry median. Based on the distribution chart, Oriola ranks #563 out of 656 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Oriola has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Oriola's Days Sales Outstanding compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Oriola ranks #563 out of 656 companies for Days Sales Outstanding. This places Oriola in the lower half of its industry. The industry median Days Sales Outstanding is 47.36. Oriola's value of 603.43 is 1174.3% above this benchmark. Historically, Oriola's own Days Sales Outstanding has ranged from 38.11 to 110.94 over the past decade. While the company's 10-year median is 48.76 vs. the industry median of 47.36, Oriola has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Healthcare Providers & Services company?
The median Days Sales Outstanding among Healthcare Providers & Services companies is 47.36, based on 656 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oriola's current Days Sales Outstanding of 603.43 is 1174.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Oriola and its competitors. For the Healthcare Providers & Services industry, the median Days Sales Outstanding is 47.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oriola's current Days Sales Outstanding is 603.43, which is 1138% above median its own 10-year median of 48.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oriola stock overvalued right now?
Oriola (CHIX:ORIOLH) has a current Days Sales Outstanding of 603.43. The stock's GF Value™ is €0.72, compared to a current price of €0.94 — trading 30.3% above its estimated fair value. The current Days Sales Outstanding is 603.43, which is 1138% above median its 10-year median of 48.76 and 1174.3% above the Healthcare Providers & Services industry median of 47.36. Oriola's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Oriola (CHIX:ORIOLH), the current Days Sales Outstanding is 603.43 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oriola (CHIX:ORIOLH) Overvalued in 2026?
Based on GuruFocus' analysis, Oriola stock appears to be overvalued.
The current stock price of €0.94 is trading 30.3% above its estimated GF Value™ of €0.72.
Key valuation signals for CHIX:ORIOLH:
Days Sales Outstanding: 603.43 (1138% above median its 10-year median of 48.76)
GF Value™: €0.72 vs. price of €0.94 (30.3% above fair value)
Industry Position: 1174.3% above the Healthcare Providers & Services median (#563 of 656)
No single metric tells the full story. See the CHIX:ORIOLH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oriola Corp is a health and wellbeing company operating in Nordic countries. It offers services such as the distribution of pharmaceuticals and other health and well-being products, services, and dose dispensing. Oriola's operations are divided into two segments which include distribution and wholesale. Geographically, the company operates in Sweden, Finland and other countries generating majority revenue from the region of Sweden.
38GF Score
Get the complete analysis for CHIX:ORIOLH
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ORIOLH has been successfully added to your 
